

Pembrolizumab KEYNOTE-040

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-040

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Head and neck cancer  
 Therapeutic Indication: Recurrent or metastatic SCCHN in adults whose tumours express PD-L1 with a  $\geq 50\%$  TPS and progressing on or after platinum-containing ChT  
 Experimental Arm: Pembrolizumab  
 Control Arm: Standard of care (methotrexate, docetaxel or cetuximab)



